Carcinosarcomas and Related Cancers: Tumors Caught in the Act of Epithelial-Mesenchymal Transition
Authors:
- 10 January 2018
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (2) , 210-216
Abstract
In this review, we outline the biology and management of patients with carcinosarcomas and related malignancies, which are often included under the broader concept of sarcomatoid carcinomas. Carcinosarcomas are unusual tumors that are commonly gynecologic in origin, where they are referred to as malignant mixed Müllerian tumors, but may appear in any anatomic site. Although a variety of hypotheses have been presented as to the biphasic nature of these tumors, carcinosarcomas seem to represent the best example in human cancers of the concept of epithelial-mesenchymal transition (EMT), in which the two parts of the tumor are genomically related to one another, as opposed to the mesenchymal component that represents a second neoplasm or (benign) reactive process. In general, patients with carcinosarcomas fare worse than patients with carcinomas of the same anatomic site. Treatment paradigms for carcinosarcomas generally follow those of carcinomas of the same organ site, except where clinical trials provide more specific options. Agents that block or reverse EMT are worth examination in patients with carcinosarcoma and arguably may be even more effective in carcinomas, given evidence of dependence on EMT to generate successful metastases. Information about EMT may also inform other phase transitions in cancer, such as those between prostate or lung carcinoma and more aggressive tumors with neuroendocrine differentiation.Keywords
This publication has 43 references indexed in Scilit:
- Clinical Outcomes with Perioperative Chemotherapy in Sarcomatoid Carcinomas of the LungJournal of Thoracic Oncology, 2012
- A Phase II Trial of Paclitaxel and Carboplatin in Women With Advanced or Recurrent Uterine CarcinosarcomaInternational Journal of Gynecological Cancer, 2011
- A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802Medical Oncology, 2011
- Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2010
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874)European Journal of Cancer, 2008
- A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I–IV carcinosarcoma (CS) of the uterus☆Gynecologic Oncology, 2007
- Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2007
- Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor MetastasisCell, 2004
- Doxorubicin and Ifosfamide in Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: A Phase II Study of the Genitourinary Group of the French Federation of Cancer CentersJournal of Urology, 2002